A wireless implant helped patients with severe macular degeneration regain usable vision. The results point toward a new ...

The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...

MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the ...

AI-powered retinal imaging closes healthcare gaps, enables earlier intervention, and reveals new insights into systemic diseases across diverse populations.

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

The eye is made up of several different parts. One of these parts is the retina, which is home to special nerve cells that respond to light. The macula is part of that network and is located in the ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...